Off-Label Ltd

subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

UK search results

Number of records found 60

Select ID for details Off-label therapeutic category Subcategory Drug Reported off-label use
6458 Cardiovascular Pericardium Mitomycin C Case report of the intraperitoneal installation of mitomycin C in a female patient with recurrent cardiac tamponade due to malignant pericardial effusion
5883 Eye Lacrimal Mitomycin C Prospective study to observe the effect of intraoperative mitomycin C (0.05 mg/ml and 0.4 mg/ml) on postoperative ostium size after external dacryocystorhinostomy
6308 Eye Glaucoma Mitomycin C Case report of the development of early-onset sclerolimbal ectasia following the use of topical mitomycin C (0.02%) during uveitic glaucoma surgery (ALERT) (SUBPOP)
7411 Eye Lacrimal Mitomycin C Randomized controlled trial to assess the long term results of intraoperative mitomycin C during external dacryocystorhinostomy (EXT-DCR) (0.2 mg/ml applied to the osteotomy site for thirty minutes) in thirty-five patients with primary acquired nasolacrimal duct obstruction (ANDO) (The investigators conclude that intraoperative mitomycin C appears to enhance outcomes following EXT-DCR surgery in patients with primary ANDO)
7735 Eye Glaucoma Mitomycin C Randomized controlled trial to evaluate the pressure-lowering effect and safety of the postoperative application of mitomycin C (0.05 mg/ml applied topically to the filtering bleb for five minutes daily for three days postoperatively) following routine trabeculectomy (The investigators report that the postoperative application of mitomycin C reduced the intraocular pressure without increasing the rate of complications)
282 Eye Cornea Mitomycin C Prophylactic use in wave front-guided photorefractive keratectomy (Topical)
283 Eye Cornea Mitomycin C Single application following scraping of the corneal surface to treat haze and regression after photorefractive keratectomy for myopia (Topical, 0.02% in a merocel sponge)
286 Eye Glaucoma Mitomycin C Augmentation of trabeculectomy for neovascular glaucoma (Topical administration)
306 Eye Pterygium Mitomycin C Adjunct therapy in the surgical treatment of recurrent pterygium (Topical administration)*
1555 Eye Glaucoma Mitomycin C Adjunctive therapy during trabeculectomy in children with primary congenital glaucoma (Topical administration)
1607 Eye Conjunctiva Mitomycin C As an adjunct to papillary resection in preventing recurrence of corneal lesions and regrowth of papillae in patients with severe atopic and vernal keratoconjunctivitis (Application to palpebral conjunctiva immediately after papillary excision)
1246 Eye Glaucoma Mitomycin C In conjunction with fluorouracil to reduce intraocular pressure after glaucoma surgery (Topical administration)
1248 Eye Glaucoma Mitomycin C Uveitic glaucoma
3379 Eye Pterygium Mitomycin C Intraoperative administration (0.02% w/w for five minutes) during surgery for excision of pterygium (Topical administration)
3380 Eye Pterygium Mitomycin C Postoperative administration (1% or 2% w/w four times daily for two weeks) following excision of pterygium (Topical administration)
3428 Eye Cornea Mitomycin C Topical application in conjunction with phototherapeutic keratectomy for the treatment of recurrent Reis-Bucklers dystrophy
3297 Eye Cornea Mitomycin C Brushstroke application of mitomycin C (0.01%) as adjunct with laser epithelial keratomileusis (LASEK)
4094 Eye Pterygium Mitomycin C To assess the efficacy and safety of amniotic membrane graft combined with intraoperative mitomycin C (0.025% for three minutes) to prevent recurrence after excision of recurrent pterygia
4686 Eye Conjunctiva Mitomycin C Case reports of the use of intraoperative mitomycin C (Application of 0.04% w/v for five minutes in the deep fornix after excision of subconjunctival fibrovascular tissues) to enhance amniotic membrane transplantation in symblepharon lysis and fornix reconstruction in patients with severe cicatricial ocular surface diseases associated with burns, pterygia, Stevens-Johnson syndrome and pemphigoid
4995 Eye Pterygium Mitomycin C Randomized controlled trial comparing the efficacy of mitomycin C (0.02%) and doxorubicin (0.02%) to prevent the recurrence of primary pterygium when administered intraoperatively for three minutes during surgical excision (Topical administration)
5328 Eye Conjunctiva Mitomycin C Randomized controlled trial to evaluate the efficacy and safety of topical mitomycin C to control acute exacerbations in patients with severe vernal keratoconjunctivitis that was refractory to conventional treatment
5548 Eye Cornea Mitomycin C Retrospective review of consecutive cases to determine the safety and efficacy of the use of intraoperative mitomycin C during phototherapeutic keratectomy for anterior corneal disease
5549 Eye Cornea Mitomycin C Randomized controlled trial to determine whether there is an increased risk to the corneal endothelium when mitomycin C (0.02% for thirty seconds) is administered after photorefractive keratectomy (ALERT)
4519 Eye Glaucoma Mitomycin C Open study to evaluate the effectiveness and safety of adjunctive mitomycin C (0.5 mg/ml) in Ahmed glaucoma valve implantation for the management of refractory glaucoma (Topical administration)
5747 Gastrointestinal & Liver Oesophagus Mitomycin C Preliminary prospective study of locally-applied mitomycin C as a conservative treatment for refractory oesophageal strictures in children (Intraoesophageal administration)
7362 Gastrointestinal & Liver Oesophagus Mitomycin C Case series of eight patients with oesophageal stenosis (six cases due to caustic stenosis, and two with sequelae of oesophageal atresia) whose treatment included the topical application of mitomycin C (0.4 mg/ml applied to the dilated site in 5-10 ml over five minutes using a flexible fibroscope) (The authors report that their results from this case series support the use of topical mitomycin to prolong symptom-free periods following dilatation)
6013 Gastrointestinal & Liver Oesophagus Mitomycin C Case report of a child with a distal oesophageal stricture (20% of oesophageal diameter despite repeated dilatations) following caustic ingestion who was treated with topically-applied mitomycin C by endoscopy, enabling the child to resume normal eating, with a demonstrable decrease in stenosis (50% of oesophageal diameter)
7223 Genito-Urinary & Renal Urethra Mitomycin C Randomized controlled trial to evaluate the efficacy of mitomycin C (0.1 mg injected submucosally) to prevent stricture recurrence in forty male patients with anterior urethral stricture undergoing internal urethrotomy under direct vision (Urethral stricture recurred in two patients (10%) in the surgery plus mitomycin C group and in ten patients (50%) in the surgery-only group (p=0.006))
6889 Head & Neck (including ENT) Sinus Mitomycin C Prospective open label study to evaluate the efficacy of topical mitomycin C in reducing frontal ostium topical stenosis following endoscopic sinus surgery (These investigators report that application of mitomycin C solution achieved a patency rate of 86% and conclude that the role of mitomycin C in reducing scarring may obviate the need for repeated surgery)
6090 Head & Neck (including ENT) Sinus Mitomycin C Controlled study to assess the short and long term effects of topically administered mitomycin (0.4 mg/ml applied for five minutes) in maintaining the patency of a middle meatal antrostomy in patients with chronic sinusitis after endoscopic sinus surgery
6538 Head & Neck (including ENT) Larynx Mitomycin C Case report of a middle-aged man with a laryngeal web that was treated with endoscopy lysis plus a topical application of mitomycin C to prevent anterior glottic restenosis
5822 Head & Neck (including ENT) Larynx Mitomycin C Retrospective chart review to evaluate whether topical mitomycin C is an effective adjuvant therapy in the treatment of patients with laryngotracheal stenosis
3859 Head & Neck (including ENT) Sinus Mitomycin C To assess whether the topical application of mitomycin C (using a pledget soaked in 0.5% w/w and inserted into the middle meatus of the nasal cavity for 5 minutes) reduces the incidence of stenosis and synechia following endoscopic sinus surgery (Topical administration)
3665 Head & Neck (including ENT) Larynx Mitomycin C Treatment of anterior glottic synechia that was secondary to frontolateral laryngectomy, transoral laser therapy for laryngeal papillomatosis, or bilateral glottic carcinoma (Topical administration to anterior glottis)
2234 Head & Neck (including ENT) Larynx Mitomycin C In combination with carbon dioxide laser therapy and dilatation as adjuvant treatment in the endoscopic management of laryngeal and tracheal stenosis (Topical administration)
466 Immune Dysfunction & Allergic Disorders Granulomatous Mitomycin C Laryngeal sarcoidosis*
1906 Malignant Disease Genitalia (Female) Mitomycin C In combination with radiation therapy and fluorouracil as primary, adjuvant, and salvage therapy for vulvar squamous cell carcinoma
1907 Malignant Disease Genitalia (Female) Mitomycin C Single agent in combination with radiation therapy as primary, adjuvant, and salvage therapy for vulvar squamous cell carcinoma
2131 Malignant Disease Biliary Mitomycin C In combination with capecitabine for the treatment of previously untreated patients with advanced biliary tract cancer
2133 Malignant Disease Biliary Mitomycin C In combination with gemcitabine for the treatment of previously untreated patients with advanced biliary tract cancer
2208 Malignant Disease Pleura Mitomycin C As a component in an MVP regimen consisting of mitomycin C every 6 weeks, vinblastine every 3 weeks and cisplatin every 3 weeks for the palliation of symptoms in patients with inoperable malignant pleural mesothelioma
2800 Malignant Disease Gastric Mitomycin C Preoperative intraperitoneal chemotherapy consisting of mitomycin C (20 mg) and cisplatin (10 mg) for the treatment of patients with serosa-infiltrating gastric cancer (Intraperitoneal administration)
3238 Malignant Disease Peritoneum Mitomycin C Administration of mitomycin C adsorbed onto carbon particles, directly into the abdominal cavity of patients with peritoneal carcinomatosis associated with gastric cancer (Intraperitoneal administration)
1537 Malignant Disease Cancer prevention Mitomycin C Conjunctival-corneal intraepithelial neoplasia (Topical administration)
3664 Malignant Disease Toxicity prophylaxis Mitomycin C Prevention of anterior glottic synechia in patients with glottic carcinoma treated by transoral laser surgery (Topical administration to anterior glottis)
3762 Malignant Disease Uterus Mitomycin C Regimen consisting of cisplatin and mitomycin C administered using intraperitoneal hyperthermic perfusion following cytoreductive surgery for the treatment of patients with uterine sarcoma
1305 Malignant Disease Vagina Mitomycin C Primary invasive squamous carcinoma of the vagina*
4125 Malignant Disease Pericardium Mitomycin C To evaluate the efficacy and safety of mitomycin C (2 mg) for the local control of malignant pericardial effusion administered by direct instillation into the pericardial space in patients with advanced non-small cell lung cancer (Intrapericardial administration)
5811 Malignant Disease Eye Mitomycin C Case reports of the adjunctive use of topical ciclosporin A (0.05% four times a day for twelve weeks) with topical mitomycin C (0.01% four times a day at the second, fourth and sixth weeks of treatment) for the treatment of patients with diffuse conjunctival and corneal squamous cell carcinoma
4605 Malignant Disease Ovary Mitomycin C Preliminary evaluation of the activity of irinotecan (140 mg/m2) in combination with mitomycin (7 mg/m2) on days 1, 15, and 29 until disease progression or the development of unacceptable toxicity, for the treatment of patients with platinum-refractory ovarian cancer
5735 Malignant Disease Peritoneum Mitomycin C Case reports of the use of laparoscopic intraperitoneal hyperthermic chemotherapy (cisplatin, doxorubicin or mitomycin C administered at 42 degrees centigrade for ninety minutes with 1.5% dextrose solution as carrier) for the palliation of debilitating malignant ascites in patients with advanced cancer (Intracavitary, intraperitoneal administration)
5900 Malignant Disease Peritoneum Mitomycin C Prospective comparative study evaluating the safety and efficacy of hyperthermic intraperitoneal chemotherapy using either mitomycin C or oxaliplatin for the treatment of patients with peritoneal carcinomatosis of colorectal origin
5902 Malignant Disease Gastric Mitomycin C Case series of the use of adjuvant hyperthermic intraperitoneal intraoperative administration of mitomycin C, together with radical surgery for the treatment of locally advanced gastric cancer
6592 Malignant Disease Eye Mitomycin C Open label prospective study to evaluate the efficacy of topical mitomycin C (0.04% four times daily) for the treatment of conjunctival tumours
6893 Malignant Disease Cancer prevention Mitomycin C Case report of an eighty-two year old woman with extensive conjunctiva-cornea intraepithelial neoplasia who was successfully managed with two cycles of topical mitomycin C (0.02%), followed by topical interferon alfa-2b (1 million IU/ml four times daily) until tumour disappearance
5557 Respiratory Granulomatous Mitomycin C Case report of the use of topical mitomycin C (Two minute application of a saturated pledget containing 0.5 mg/ml) to treat obstructing granulomas in the lower trachea and main bronchi of an elderly woman with post-tuberculous stricture who had previously undergone laser recanalization and silicone stent implantation (Intrapulmonary administration)
4438 Skin Keloid Mitomycin C Preliminary assessment of the efficacy of mitomycin C to prevent the recurrence of surgically excised keloid scars (Following excision a pledget containing 1 ml of 0.4% solution was applied for five minutes prior to skin closure (Topical administration)
6915 Skin Keloid Mitomycin C Case series of ten patients with keloids of the head and neck who were treated with surgical excision together with application of topical mitomycin C (These investigators report that mitomycin C is an effective therapy for the prevention of keloid recurrence of the head and neck)
7220 Skin Haemangioma Mitomycin C Open label study to evaluate the efficacy of mitomycin C drops (0.02% applied four times daily in fifteen-day cycles with intervals of fifteen days between each cycle) in six patients with pyogenic granuloma in an ophthalmic socket (One patient had complete resolution after ten days treatment, two patients had successful outcomes after one cycle, two patients had successful outcomes at the beginning of the second cycle, and one patient had a lesion that persisted after two cycles of treatment)
7686 Skin Keloid Mitomycin C Open label study to determine whether application of topical mitomycin C (1 mg/ml for three minutes) to the base of shave-removed keloid scars in ten patients prevents their recurrence (The investigators report that this new treatment has been shown to be effective in the majority of patients, but further studies are required to confirm this benefit)

Definition of descriptors (where appropriate):

*The reported drug was used as part of a combined therapy regimen

SUBPOP Variability in response may represent responding/nonresponding patient subgroups
ALERT Potential for remarkable and/or significant toxicity

 

 

 

About Us |Privacy Policy | Contact Us | ©2008 Off-Label Ltd